169 related articles for article (PubMed ID: 37569459)
1. A Functional Pipeline of Genome-Wide Association Data Leads to Midostaurin as a Repurposed Drug for Alzheimer's Disease.
Esteban-Martos A; Brokate-Llanos AM; Real LM; Melgar-Locatelli S; de Rojas I; Castro-Zavala A; Bravo MJ; Mañas-Padilla MDC; García-González P; Ruiz-Galdon M; Pacheco-Sánchez B; Polvillo R; Rodriguez de Fonseca F; González I; Castilla-Ortega E; Muñoz MJ; Rivera P; Reyes-Engel A; Ruiz A; Royo JL
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569459
[TBL] [Abstract][Full Text] [Related]
2. Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer's disease.
Fang J; Zhang P; Wang Q; Chiang CW; Zhou Y; Hou Y; Xu J; Chen R; Zhang B; Lewis SJ; Leverenz JB; Pieper AA; Li B; Li L; Cummings J; Cheng F
Alzheimers Res Ther; 2022 Jan; 14(1):7. PubMed ID: 35012639
[TBL] [Abstract][Full Text] [Related]
3. Single-cell-led drug repurposing for Alzheimer's disease.
Parolo S; Mariotti F; Bora P; Carboni L; Domenici E
Sci Rep; 2023 Jan; 13(1):222. PubMed ID: 36604493
[TBL] [Abstract][Full Text] [Related]
4. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
Shoaib M; Kamal MA; Rizvi SMD
Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
[TBL] [Abstract][Full Text] [Related]
5. Drug repurposing on Alzheimer's disease through modulation of NRF2 neighborhood.
Bourdakou MM; Fernández-Ginés R; Cuadrado A; Spyrou GM
Redox Biol; 2023 Nov; 67():102881. PubMed ID: 37696195
[TBL] [Abstract][Full Text] [Related]
6. Combinational Drug Repurposing from Genetic Networks Applied to Alzheimer's Disease.
Nabirotchkin S; Bouaziz J; Glibert F; Mandel J; Foucquier J; Hajj R; Callizot N; Cholet N; Guedj M; Cohen D
J Alzheimers Dis; 2022; 88(4):1585-1603. PubMed ID: 35811522
[TBL] [Abstract][Full Text] [Related]
7. Interpretable deep learning translation of GWAS and multi-omics findings to identify pathobiology and drug repurposing in Alzheimer's disease.
Xu J; Mao C; Hou Y; Luo Y; Binder JL; Zhou Y; Bekris LM; Shin J; Hu M; Wang F; Eng C; Oprea TI; Flanagan ME; Pieper AA; Cummings J; Leverenz JB; Cheng F
Cell Rep; 2022 Nov; 41(9):111717. PubMed ID: 36450252
[TBL] [Abstract][Full Text] [Related]
8. Repurposed agents in the Alzheimer's disease drug development pipeline.
Bauzon J; Lee G; Cummings J
Alzheimers Res Ther; 2020 Aug; 12(1):98. PubMed ID: 32807237
[TBL] [Abstract][Full Text] [Related]
9. Old Drugs with New Tricks: Paradigm in Drug Development Pipeline for Alzheimer's Disease.
Dalvi T; Dewangan B; Das R; Rani J; Shinde SD; Vhora N; Jain A; Sahu B
Cent Nerv Syst Agents Med Chem; 2020; 20(3):157-176. PubMed ID: 33087034
[TBL] [Abstract][Full Text] [Related]
10. Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort.
Cong W; Meng X; Li J; Zhang Q; Chen F; Liu W; Wang Y; Cheng S; Yao X; Yan J; Kim S; Saykin AJ; Liang H; Shen L;
BMC Genomics; 2017 May; 18(1):421. PubMed ID: 28558704
[TBL] [Abstract][Full Text] [Related]
11. Medical genetics-based drug repurposing for Alzheimer's disease.
Zhang XZ; Quan Y; Tang GY
Brain Res Bull; 2015 Jan; 110():26-9. PubMed ID: 25446738
[TBL] [Abstract][Full Text] [Related]
12. Functional enrichment analysis of three Alzheimer's disease genome-wide association studies identities DAB1 as a novel candidate liability/protective gene.
Gao H; Tao Y; He Q; Song F; Saffen D
Biochem Biophys Res Commun; 2015 Aug; 463(4):490-5. PubMed ID: 26028559
[TBL] [Abstract][Full Text] [Related]
13. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients.
Bayraktar A; Li X; Kim W; Zhang C; Turkez H; Shoaie S; Mardinoglu A
J Transl Med; 2023 May; 21(1):332. PubMed ID: 37210557
[TBL] [Abstract][Full Text] [Related]
14. Computational Drug Repurposing for Alzheimer's Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies.
Xu Y; Kong J; Hu P
Front Pharmacol; 2021; 12():617537. PubMed ID: 34276354
[No Abstract] [Full Text] [Related]
15. Genome-wide association reveals genetic effects on human Aβ42 and τ protein levels in cerebrospinal fluids: a case control study.
Han MR; Schellenberg GD; Wang LS;
BMC Neurol; 2010 Oct; 10():90. PubMed ID: 20932310
[TBL] [Abstract][Full Text] [Related]
16. Repurposing ibudilast to mitigate Alzheimer's disease by targeting inflammation.
Oliveros G; Wallace CH; Chaudry O; Liu Q; Qiu Y; Xie L; Rockwell P; Figueiredo-Pereira ME; Serrano PA
Brain; 2023 Mar; 146(3):898-911. PubMed ID: 35411386
[TBL] [Abstract][Full Text] [Related]
17. Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: a Mendelian randomization study.
Walker VM; Kehoe PG; Martin RM; Davies NM
Int J Epidemiol; 2020 Aug; 49(4):1132-1140. PubMed ID: 31335937
[TBL] [Abstract][Full Text] [Related]
18. An analysis of genetically regulated gene expression across multiple tissues implicates novel gene candidates in Alzheimer's disease.
Gerring ZF; Lupton MK; Edey D; Gamazon ER; Derks EM
Alzheimers Res Ther; 2020 Apr; 12(1):43. PubMed ID: 32299494
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Targeting of Repurposed Anticancer Drugs in Alzheimer's Disease: Using the Multiomics Approach.
Advani D; Kumar P
ACS Omega; 2021 Jun; 6(21):13870-13887. PubMed ID: 34095679
[TBL] [Abstract][Full Text] [Related]
20. The TRiC/CCT chaperone is implicated in Alzheimer's disease based on patient GWAS and an RNAi screen in Aβ-expressing Caenorhabditis elegans.
Khabirova E; Moloney A; Marciniak SJ; Williams J; Lomas DA; Oliver SG; Favrin G; Sattelle DB; Crowther DC
PLoS One; 2014; 9(7):e102985. PubMed ID: 25080104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
